Introduction

When exploring innovative mental health treatments like Transcranial Magnetic Stimulation (TMS), patients often seek insights from multiple perspectives. What does the science tell us? How does the treatment work in practice? What's the patient experience really like?

To provide these diverse viewpoints, we've assembled a series of interviews with specialists connected to Neuralia TMS Melbourne, which opened in December 2023 as "Cortical TMS powered by Neuralia." Each expert offers a unique lens on this non-invasive treatment approach now available in Moonee Ponds.

From neuroscience foundations to practical logistics, from clinical applications to financial considerations, these conversations create a comprehensive picture of TMS therapy as provided at Neuralia's Melbourne clinic.

Note: These interviews present composite perspectives based on typical professional roles in TMS treatment. They represent the range of expertise involved but do not depict specific individuals.

 

The Neuroscientist: Understanding the Brain Science Behind TMS

Interviewer: Thank you for joining us to discuss the science behind TMS. Could you start by explaining the basic mechanism of how TMS affects the brain?

Neuroscientist: At its core, TMS works through electromagnetic induction—a principle discovered back in the 1830s by Michael Faraday. The TMS device generates a powerful but focused magnetic field that passes through the skull without being blocked by bone, unlike electrical current. When this magnetic field reaches brain tissue, it induces small electrical currents that cause neurons to fire.

What makes TMS therapeutically valuable is that we can target specific brain regions. For instance, in depression treatment, we typically target the dorsolateral prefrontal cortex—an area that often shows reduced activity in depression. By repeatedly stimulating this region over multiple sessions, we can essentially "exercise" those neural circuits, promoting what we call neuroplasticity.

Interviewer: Could you explain neuroplasticity in simpler terms?

Neuroscientist: Certainly. Neuroplasticity refers to the brain's remarkable ability to reorganize itself by forming new neural connections and modifying existing ones. It's the mechanism through which we learn new skills, form memories, and adapt to changing circumstances.

With TMS, we're harnessing this natural capacity. By repeatedly activating specific neural circuits, we encourage them to strengthen—similar to how physical exercise strengthens muscles. Over a course of treatment, these stimulated circuits become more efficient and effective, potentially normalizing brain function that has been disrupted in conditions like depression or anxiety.

Interviewer: How does the neuroscience differ between treating various conditions like depression versus anxiety or OCD?

Neuroscientist: That's an excellent question. Different mental health conditions involve different brain circuits and patterns of dysfunction. In depression, as I mentioned, the dorsolateral prefrontal cortex often shows reduced activity. In anxiety disorders, we might see hyperactivity in regions involved in threat detection and fear processing. OCD involves dysfunctional connectivity between regions governing impulse control and emotional responses.

TMS protocols are customized accordingly. For depression, we typically use high-frequency stimulation to increase activity in underactive regions. For some anxiety conditions, we might use low-frequency stimulation to reduce hyperactivity in overactive areas. The location, frequency, intensity, and pattern of stimulation can all be tailored to address the specific neural dysfunctions associated with each condition.

Interviewer: What distinguishes TMS from medication approaches at the neurobiological level?

Neuroscientist: The fundamental difference is precision. Medications affect neurotransmitter systems throughout the entire brain and body, which is why they often cause systemic side effects like weight gain, sexual dysfunction, or gastrointestinal issues. They essentially create a brain-wide chemical change in hopes of affecting the circuits involved in the condition.

TMS, by contrast, directly targets specific brain regions. The effects are localized to the stimulated area and connected circuits, largely sparing uninvolved regions. This targeted approach explains why TMS typically causes fewer side effects than medications.

Another important distinction is that medications primarily affect chemical signaling between neurons, whereas TMS directly influences electrical activity patterns. Some conditions may involve problems with neural activity patterns that aren't fully addressed by altering neurotransmitter levels, which might explain why TMS sometimes helps patients who haven't responded to medications.

Interviewer: How does current research inform the TMS protocols used at Neuralia Melbourne?

Neuroscientist: TMS has been researched for over 35 years, with the first clinical applications emerging in the mid-1990s. This research has progressively refined our understanding of optimal treatment parameters for different conditions.

At Neuralia Melbourne, the protocols are based on this established research, including parameters that have been validated in clinical trials and received regulatory approval. The standard protocol for depression, for instance, involves high-frequency stimulation of the left dorsolateral prefrontal cortex, delivered in sessions lasting approximately 30 minutes, typically five days per week for 4-6 weeks.

However, the field continues to evolve. Newer approaches like theta-burst stimulation deliver patterns of pulses that more closely mimic natural brain rhythms, potentially producing effects more efficiently. Research also continues to refine targeting methods, treatment durations, and maintenance strategies. Clinics like Neuralia stay connected to this evolving research landscape while ensuring their core protocols remain grounded in established evidence.

 

The TMS Psychiatrist: Clinical Applications and Treatment Planning

Interviewer: As a TMS psychiatrist, you evaluate patients and develop treatment plans. What makes someone a good candidate for TMS therapy?

TMS Psychiatrist: The ideal candidate varies somewhat depending on the condition we're treating. For depression, which is our most common application and the one covered by Medicare, we typically look for patients who haven't responded adequately to antidepressant medications. The formal criterion is having tried at least two different antidepressants at adequate doses and durations without satisfactory improvement—what we call treatment-resistant depression.

Beyond that specific criterion, we consider several factors. We look for patients who are stable enough to commit to the treatment schedule, which typically involves sessions five days a week for several weeks. We assess for any contraindications like metal implants in or near the head, a history of seizures, or certain neurological conditions.

We also consider the nature of the symptoms. TMS tends to be particularly effective for core symptoms of depression like low mood, anhedonia (inability to feel pleasure), fatigue, and concentration difficulties. It can help with anxiety, certain forms of insomnia, and other symptoms as well, but those core depressive symptoms are where we often see the most robust response.

Interviewer: What does the initial assessment process look like at Neuralia TMS Melbourne?

TMS Psychiatrist: The process begins with a referral from a GP or psychiatrist. Once we receive that, we schedule a comprehensive initial consultation, which typically lasts 45-60 minutes. During this appointment, I review the patient's complete psychiatric history, including previous treatments and their outcomes. I assess current symptoms using standardized measures and clinical interview techniques. I also review medical history to ensure there are no contraindications to TMS treatment.

If the patient appears to be a suitable candidate, I explain how TMS works and what they can expect during treatment. We discuss potential benefits and risks, the time commitment involved, and what a typical response timeline might look like. I answer any questions they might have and ensure they have realistic expectations about the treatment.

If we decide to proceed, we schedule a mapping session. This is where we locate the exact treatment spot on the scalp and determine the appropriate stimulation intensity for that individual. This personalization is crucial—every brain is slightly different in size and structure, and people vary in their neural excitability.

Interviewer: Could you walk us through how you monitor progress and adjust treatment during a typical course?

TMS Psychiatrist: Progress monitoring is continuous throughout the treatment course. At regular intervals, typically weekly, we administer standardized rating scales to track symptom changes objectively. These might include depression scales like the PHQ-9 or anxiety measures like the GAD-7, depending on the primary condition being treated.

Beyond these formal measures, we conduct brief clinical assessments before each session, checking for any side effects and noting any changes the patient has observed. It's important to remember that improvement with TMS is typically gradual rather than sudden, so we're looking for progressive changes over time rather than dramatic shifts after a single session.

If we're not seeing the expected improvement by about the midpoint of treatment, we might consider adjustments. This could involve fine-tuning the coil location, adjusting the stimulation intensity, or modifying the protocol parameters like pulse frequency or pattern. We balance following established protocols with making reasonable adjustments based on individual response patterns.

Interviewer: What conditions does Neuralia TMS Melbourne treat beyond depression?

TMS Psychiatrist: While depression—particularly treatment-resistant depression—is our primary focus and the condition covered by Medicare, we also provide TMS for several other conditions.

We offer protocols for various anxiety disorders, using precisely targeted stimulation to help regulate brain circuits involved in anxiety responses. We treat post-traumatic stress disorder (PTSD), addressing the neurological aspects of trauma responses. For obsessive-compulsive disorder (OCD), we provide tailored TMS protocols that target the specific brain circuits involved in obsessive thoughts and compulsive behaviors.

We also offer TMS therapy for certain chronic pain conditions, particularly those with a strong central nervous system component. By targeting brain regions involved in pain processing and perception, TMS can help modulate pain signals and potentially reduce symptom severity.

For all these applications, the scientific evidence is at different stages of development. The strongest evidence is for depression, which is why that's the Medicare-approved indication. But there's growing research support for these other applications, and many patients who haven't found relief through conventional approaches consider TMS a valuable alternative worth exploring.

 

The TMS Technician: The Day-to-Day Treatment Experience

Interviewer: As someone who delivers TMS treatments daily, what does a typical session look like from start to finish?

TMS Technician: A standard session at Neuralia TMS Melbourne follows a consistent structure to ensure both effectiveness and comfort. When patients arrive, we briefly check in about how they're doing and whether they've noticed any changes or side effects since their last session. This information helps us track progress and address any concerns promptly.

The patient then sits in our specialized TMS chair, which is designed for comfort during the 30-minute session. We use the measurements and markers established during the mapping session to position the magnetic coil precisely over the target area on the scalp. Consistent positioning is crucial for treatment effectiveness, so we take this step very seriously.

Once the coil is correctly positioned, we review the treatment parameters prescribed by the TMS psychiatrist. These include the stimulation intensity (based on the patient's motor threshold), frequency, and overall pulses to be delivered.

When treatment begins, the patient feels a tapping sensation on their scalp and hears clicking sounds as the device delivers magnetic pulses. We provide earplugs to minimize this noise. Throughout the session, we monitor the patient's comfort and make minor adjustments if needed. Many patients read, listen to music, or simply relax during treatment.

After the prescribed pulses have been delivered, we remove the coil, check in with the patient about their experience during that session, and schedule their next appointment. The entire process typically takes about 30-40 minutes from arrival to departure.

Interviewer: What sensations do patients typically experience during treatment, and how do you help manage any discomfort?

TMS Technician: The most common sensation is a tapping or knocking feeling where the coil contacts the scalp. Some patients describe it as similar to a woodpecker tapping or like someone lightly flicking their finger against the scalp. The muscles in the scalp contract slightly with each pulse, creating this sensation.

During the first few sessions, many patients find this feeling unusual or mildly uncomfortable. It's rarely described as painful, but it can take some getting used to. The good news is that most patients adapt quickly, with the sensation becoming much more tolerable after 3-5 sessions as they get accustomed to it.

To manage discomfort, we have several approaches. We can start at a slightly lower intensity and gradually increase to the target level over the first few sessions. We can adjust the coil position slightly while still maintaining effective treatment. For some patients, a thin cushion between the coil and scalp can help without significantly reducing the magnetic field strength.

We also explain what to expect very clearly before starting, which helps reduce anxiety about the sensations. And we remind patients that mild discomfort during sessions doesn't mean damage is occurring—it's simply the sensory experience of the magnetic pulses activating nerves in the scalp.

Interviewer: How do you track patients' progress from your perspective as someone who sees them regularly?

TMS Technician: Seeing patients nearly every day gives us a unique window into their progress. We notice changes that might develop gradually and that the patients themselves sometimes don't immediately recognize.

We track several indicators informally. Physical presentations often change first—patients may arrive with improved posture, more animated facial expressions, or more energy in their movements. Engagement patterns shift too; someone who was withdrawn and minimal in conversation might gradually become more talkative and interactive.

We also note lifestyle changes that patients mention—sleeping better, resuming activities they'd abandoned, reconnecting with friends, or returning to hobbies they once enjoyed. These real-world functional improvements often begin before patients report significant mood changes on formal assessments.

We document these observations and share them with the TMS psychiatrist, providing valuable qualitative data to complement the standardized measures. Sometimes we can highlight improvements that patients haven't fully recognized themselves, which can be encouraging for them to hear.

Interviewer: What advice do you typically give patients to help them get the most from their TMS treatment?

TMS Technician: Consistency is probably the most important factor. Attending all scheduled sessions without extended breaks maintains the momentum of neuroplastic changes we're trying to create. I encourage patients to prioritize their treatment schedule as much as possible, even when it feels challenging.

I also suggest they pay attention to subtle changes rather than expecting dramatic shifts. Maybe they slept an extra hour, had slightly more energy for daily tasks, or felt a brief moment of interest in something they used to enjoy. These small changes often precede more noticeable improvements in mood.

It's helpful when patients continue other beneficial activities during treatment—whether that's psychotherapy, appropriate exercise, regular sleep patterns, or social engagement. TMS creates a neurobiological environment where these other positive inputs can have enhanced effects.

I remind them that improvement with TMS is typically gradual rather than sudden. Some days might feel better than others, with an overall upward trend rather than a straight-line improvement. This helps manage expectations and reduce disappointment if they experience fluctuations along the way.

Finally, I encourage open communication. Reporting honestly about their experience, any side effects, and any changes they notice—positive or negative—helps us optimize their treatment and address any concerns promptly.

 

The Financial Coordinator: Understanding Costs and Coverage

Interviewer: Medicare coverage for TMS is a relatively recent development in Australia. Could you explain how this works for patients at Neuralia TMS Melbourne?

Financial Coordinator: In November 2021, TMS was listed under Medicare in Australia specifically for Treatment Resistant Depression, which was a game-changer for accessibility. For patients who meet the Medicare criteria, Neuralia TMS Melbourne provides treatment with minimal out-of-pocket expenses.

To qualify for Medicare coverage, patients need to have a diagnosis of depression that hasn't responded adequately to at least two different antidepressant medications at appropriate doses and durations. This needs to be documented by their referring doctor. The referral should clearly outline these previous treatment attempts and their outcomes.

For Medicare-eligible patients, our fee structure includes:

• Initial Consultation: $85.00 (fully covered by Medicare rebate; $0 out-of-pocket)

• TMS Mapping Session: $173.50 (fully covered by Medicare rebate; $0 out-of-pocket)

• Standard TMS Session: $148.90 (fully covered by Medicare rebate; $0 out-of-pocket)

• Follow-up Review with TMS Doctor: $85.00 (fully covered by Medicare rebate; $0 out-of-pocket)

This means that a complete course of TMS therapy—including the initial assessment, mapping, approximately 35 treatment sessions, and follow-up care—typically involves no out-of-pocket cost for Medicare-eligible patients.

Interviewer: What about patients who don't qualify for Medicare coverage or who are seeking TMS for conditions other than depression?

Financial Coordinator: For patients seeking TMS for conditions other than treatment-resistant depression, or who don't meet the specific Medicare criteria, we offer transparent self-pay options.

Treatment sessions are priced at $180 each for non-Medicare-covered services. For a standard course of approximately 35 sessions, this would total around $6,300. We also have some additional fees that may apply:

• Extended TMS Session (if needed): $180.00 (for Medicare patients: Medicare rebate $148.90; $31.10 out-of-pocket)

• Cancellation Fee (less than 24 hours notice): $50.00 (not covered by Medicare)

We recognize this represents a significant investment. To help manage this, we offer several approaches. We can provide detailed receipts that patients can submit to private health insurance, as some plans offer partial coverage for TMS therapy. We can discuss payment plans that spread costs over the treatment period. And for patients with complex situations, we explore whether any portions of their care might qualify for Medicare coverage even if the full treatment doesn't.

Interviewer: Are there any hidden costs patients should be aware of when considering TMS at Neuralia Melbourne?

Financial Coordinator: We pride ourselves on transparency, so we work hard to ensure there are no surprising costs. All standard treatment expenses are clearly outlined before beginning treatment.

Some considerations patients should be aware of: If they require extended sessions beyond the standard 30-minute treatment, there may be additional costs. If they need to travel significant distances for daily treatment, they should factor in transportation costs. And while TMS itself has minimal recovery time, some patients choose to take time off work during treatment, which could have indirect financial implications.

One important note is our cancellation policy. We reserve a 30-minute slot specifically for each patient, and with high demand for TMS services, missed appointments represent both a loss for the clinic and a missed opportunity for other patients who could have used that time. That's why we have a $50 cancellation fee for appointments canceled with less than 24 hours' notice, which isn't covered by Medicare.

We encourage patients to discuss any financial concerns openly during their initial consultation. Our goal is to make TMS therapy accessible while maintaining the high-quality care that effective treatment requires.

Interviewer: How does Neuralia TMS Melbourne help patients navigate insurance and healthcare financing options?

Financial Coordinator: We recognize that healthcare financing can be complex and sometimes stressful. Our approach involves several layers of support.

First, we provide clear documentation and guidance for Medicare claims. For eligible patients, we process these claims directly so they don't need to pay upfront and seek reimbursement—the Medicare rebate is applied immediately.

For patients with private health insurance, we help identify whether their policy includes any coverage for TMS therapy. While coverage varies widely between insurers and specific policies, we can provide the detailed documentation and coding information they need to maximize their benefits.

We also assist patients in exploring whether they might qualify for coverage through other programs such as the Department of Veterans' Affairs for veterans with service-related mental health conditions, or workers' compensation for conditions related to workplace injuries or trauma.

For patients managing out-of-pocket expenses, we offer flexible payment arrangements and can provide guidance on health-specific payment plans or medical financing options if appropriate.

Our overall philosophy is that financial concerns shouldn't be a barrier to receiving effective treatment. While we can't eliminate all costs for every patient, we work diligently to make TMS therapy as financially accessible as possible within the constraints of the current healthcare system.

 

The Referring GP: Integration with Broader Mental Health Care

Interviewer: As a GP who refers patients to Neuralia TMS Melbourne, how do you determine which patients might benefit from TMS therapy?

GP: I consider TMS for patients who fall into several categories. Most commonly, I refer patients with depression who haven't responded adequately to multiple medication trials. The formal criterion is trying at least two different antidepressants at adequate doses and durations without satisfactory improvement, but often my patients have tried many more than that before we consider TMS.

I also consider TMS for patients who cannot tolerate the side effects of antidepressant medications. Some patients experience such significant side effects—sexual dysfunction, weight gain, emotional blunting, or gastrointestinal issues—that medication becomes unsustainable even if it helps their mood.

Comorbidities play a role in my decision-making too. Patients with depression plus anxiety, PTSD, or chronic pain might be particularly good candidates for TMS, as the treatment can potentially address multiple conditions simultaneously.

I also consider practical factors like the patient's ability to commit to the treatment schedule, their proximity to the TMS clinic, and their support system during treatment. TMS requires regular attendance for several weeks, so realistic assessment of these logistical aspects is important.

Interviewer: What information do you include in a referral to ensure your patients can access Medicare-covered TMS treatment?

GP: Medicare coverage hinges on documenting treatment-resistant depression appropriately, so I'm very thorough in my referrals. I include:

• A clear diagnosis of Major Depressive Disorder or similar depressive condition

• Detailed information about previous antidepressant trials, including:

  • Specific medications prescribed

  • Dosages and durations of each trial

  • Documented outcomes (lack of efficacy or intolerable side effects)

  • Confirmation that at least two adequate trials were completed

I also include relevant information about the patient's overall mental health history, current symptoms and their severity, other treatments attempted (like psychotherapy), and any comorbid conditions that might influence treatment planning.

I explicitly request "assessment for TMS therapy" in the referral. This specific language helps ensure the referral clearly communicates the intended purpose and helps with Medicare requirements.

If I'm aware of any potential contraindications like seizure history or metal implants, I note these as well so they can be thoroughly evaluated during the initial consultation.

Interviewer: How do you coordinate care with Neuralia TMS Melbourne during and after your patient's treatment?

GP: Coordination is essential for integrated care. During the TMS course, I typically continue seeing the patient periodically to monitor overall health and manage any medications they're continuing. The Neuralia team provides updates after the initial assessment and periodically throughout treatment, which helps me stay informed about their progress.

I find it valuable to maintain open communication channels with the TMS team, especially if medication adjustments are being considered or if new symptoms emerge during treatment. This collaborative approach ensures we're not working at cross-purposes.

After treatment completion, the TMS psychiatrist provides a comprehensive summary including the treatment protocol used, the patient's response, and recommendations for ongoing care. This helps me develop an appropriate post-TMS management plan. Some patients require maintenance TMS sessions, which we coordinate together based on symptom patterns and response durability.

I also work with patients to implement strategies that might help maintain their TMS benefits—whether that's continuing psychotherapy, maintaining healthy lifestyle habits, or monitoring for early signs of symptom return that might indicate a need for additional intervention.

Interviewer: What changes do you typically observe in patients who respond well to TMS therapy?

GP: The changes can be quite remarkable in patients who respond positively. Often the first improvements involve sleep and energy levels. Patients report sleeping more soundly and feeling less fatigued during the day, which provides a foundation for other improvements.

Emotional responsiveness often returns gradually. Patients describe being able to feel genuine pleasure again in activities they once enjoyed. They might notice themselves laughing at a joke or becoming absorbed in a book—small moments of normal emotional engagement that had been absent during their depression.

Cognitive improvements are common as well. Patients report clearer thinking, better concentration, and improved decision-making ability. These changes often translate into better functioning at work or in managing household responsibilities.

Social reconnection typically follows. As energy improves and emotional numbness decreases, patients often begin reaching out to friends or family members they had withdrawn from. They become more engaged in conversations and more willing to participate in social activities.

Perhaps most significantly, many patients describe a return of hope and future orientation. Rather than seeing only a bleak continuation of their current state, they begin making plans and expressing interest in possibilities ahead—a fundamental shift from the hopelessness that characterizes severe depression.

 

The Former Patient: A Lived Experience Perspective

Interviewer: As someone who has completed a course of TMS therapy at Neuralia Melbourne, could you share what led you to consider this treatment?

Former Patient: I had been struggling with depression for nearly a decade, trying what felt like every antidepressant available. Some didn't help at all. Others helped slightly but came with side effects I couldn't tolerate long-term—weight gain that affected my health, sexual dysfunction that strained my relationship, or a kind of emotional numbness that left me feeling disconnected from my life even when the depression lifted somewhat.

Talk therapy helped me understand my patterns and develop coping strategies, but it wasn't enough on its own to lift the persistent low mood, fatigue, and lack of interest that defined my depression. I felt stuck in a cycle of trying new medications, experiencing either inadequate benefit or intolerable side effects, then trying something else.

When my psychiatrist mentioned TMS, I was initially skeptical. It sounded vaguely like those questionable brain stimulation gadgets you see advertised online. But as she explained the research behind it and the Medicare coverage that had recently become available, I became more interested. What really convinced me was learning that it didn't have the systemic side effects of medications because it worked directly on specific brain regions rather than flooding my entire body with chemicals.

After researching it myself and learning that Neuralia TMS had opened a Melbourne location, I decided it was worth trying. At that point, I had little to lose—my depression wasn't improving with conventional approaches, and the treatment would be Medicare-covered.

Interviewer: What was your experience like during the treatment course?

Former Patient: The initial consultation was thorough—much more comprehensive than I expected. The psychiatrist reviewed my entire treatment history, current symptoms, and overall health. She explained how TMS worked and what I could realistically expect. I appreciated that she didn't promise miraculous results but presented it as a treatment with good potential for someone in my situation.

The mapping session was interesting. They found the spot on my brain that controlled thumb movement by delivering test pulses and watching for my thumb to twitch. This helped them calibrate the right intensity and locate the treatment area for depression. It felt strange but not painful.

The actual treatment sessions became part of my routine. I scheduled them for 8:30 each morning before work. The tapping sensation took some getting used to—it wasn't painful but definitely noticeable. I'd describe it as someone tapping rhythmically on my scalp with a pencil eraser. By the second week, I barely noticed it. I would bring a book to read during the 30-minute sessions, which made the time pass quickly.

As for results, they developed gradually. Around session 12 or 13, I noticed I was sleeping better—falling asleep more easily and waking feeling more rested. By week four, my energy had improved noticeably. I wasn't dragging myself through the day anymore. The emotional changes came later—around session 20, I realized I was feeling genuine interest in activities again and experiencing less negative thought patterns.

Interviewer: Were there any challenges or difficulties during your treatment?

Former Patient: The biggest challenge was definitely the time commitment. Five mornings a week for seven weeks is substantial, especially since I was working full-time. I had to shift my work schedule slightly later and explain to my manager why I needed this arrangement temporarily. Fortunately, my workplace was accommodating.

The first few sessions were uncomfortable—not severely painful, but the sensation was strange enough that I found myself tensing up in anticipation of each pulse. The staff was helpful in coaching me through relaxation techniques, and by the end of the first week, this had become much less of an issue.

I experienced mild headaches after some sessions, particularly in the first two weeks. They weren't severe and responded well to regular paracetamol. By the third week, these had largely subsided.

Perhaps the most difficult aspect was the waiting period before seeing benefits. Even though I had been told improvement would likely be gradual, there were moments in the first few weeks when I questioned whether it was working at all. The staff encouraged me to watch for subtle changes and to continue with the full course even if dramatic improvements weren't immediately obvious. They were right—the changes built gradually over time rather than happening all at once.

Interviewer: How has your experience been since completing treatment? Have the benefits lasted?

Former Patient: I completed my initial TMS course about ten months ago, and I'm pleased to say that many of the benefits have persisted. My sleep quality remains much better than before treatment. My energy levels are more consistent, and I've maintained interest in activities and hobbies that I had abandoned during my depression.

I won't claim that I never have low days—I do. But they're now the exception rather than my constant state, and they typically pass more quickly. My negative thought patterns are less intense and persistent, and I'm better at recognizing and challenging them when they do occur.

About seven months after finishing the initial course, I noticed some mild symptoms returning—nothing like my previous depression, but enough that my psychiatrist and I decided a brief refresher course would be beneficial. I did ten additional TMS sessions, which helped reinforce the improvements.

I've also continued with occasional therapy, which seems more effective now that I'm not fighting through the fog of depression. The coping strategies I learned in therapy previously make more practical sense now and are easier to implement.

Perhaps most significantly, I've regained a sense of agency in my life. Rather than feeling at the mercy of my depression, I now have multiple tools and approaches that work together—TMS has been an important part of that toolkit, but not the only component. It created a neurobiological foundation that made other positive changes more accessible and sustainable.

 

The Research Psychologist: Future Directions in TMS Therapy

Interviewer: From a research perspective, how has TMS therapy evolved since its development, and how might it continue to advance?

Research Psychologist: TMS has undergone remarkable evolution since its introduction in 1985. The early applications were primarily in neuroscience research, using single pulses to map brain function. The therapeutic potential began emerging in the 1990s, with depression treatment protocols developing through the early 2000s, leading to FDA approval in 2008 and eventual Medicare listing in Australia in 2021.

The technology and protocols have refined considerably during this journey. Early devices were relatively basic, while modern systems offer more precise targeting, consistent pulse delivery, and built-in cooling systems that allow longer treatment sessions. The protocols have evolved from simple high or low-frequency stimulation to more complex patterns like theta-burst stimulation, which may produce comparable effects in shorter treatment times.

Looking forward, several exciting developments are on the horizon. Personalized targeting is advancing through neuroimaging techniques that identify individual variations in brain structure and function, potentially allowing more precise stimulation of relevant circuits. Treatment protocols are becoming more individualized based on specific symptom profiles and biological markers rather than broad diagnostic categories.

We're also seeing interesting research on combined approaches—using TMS alongside cognitive training or specific psychotherapy techniques to potentially enhance both interventions. The timing of cognitive activities in relation to brain stimulation appears to influence how effectively neuroplastic changes develop and consolidate.

Interviewer: Are there emerging applications for TMS beyond the conditions currently treated?

Research Psychologist: Absolutely. While depression remains the most established application, research is actively exploring numerous other potential uses. Some of the most promising emerging applications include:

Substance use disorders, where TMS may help reduce cravings and modify reward circuitry involved in addiction. Early research shows potential for alcohol, nicotine, and other substance dependencies.

Cognitive enhancement for neurodegenerative conditions like early Alzheimer's disease or mild cognitive impairment. Some studies suggest TMS might help maintain cognitive function or slow decline when applied to relevant brain networks.

Rehabilitation after stroke, potentially enhancing motor recovery by stimulating affected motor circuits or inhibiting maladaptive compensatory patterns that can develop after brain injury.

Certain neurological conditions like Parkinson's disease, where TMS might help manage specific symptoms by modulating relevant motor circuits.

Autism spectrum disorders, particularly for specific symptoms like repetitive behaviors or social communication challenges that involve identifiable brain networks.

Each of these applications is at a different stage of research development. Some have promising early clinical trials, while others remain more theoretical or have only preliminary evidence. The field is actively investigating optimal protocols, appropriate patient selection criteria, and expected outcomes for these emerging applications.

Interviewer: How might TMS delivery evolve in the future to improve convenience or effectiveness?

Research Psychologist: Several innovations are being explored that could significantly change how TMS is delivered. One of the most potentially transformative is accelerated TMS protocols—compressed treatment schedules that deliver multiple sessions per day over a shorter total duration, perhaps 2 weeks instead of 6-8 weeks. Early research suggests these accelerated approaches may produce comparable effects to standard protocols while requiring less total time commitment from patients.

Home-based or portable TMS devices are another area of active development. While current TMS therapy requires specialized equipment in a clinical setting, researchers are working on smaller, simpler devices that might eventually allow some forms of TMS to be delivered at home under remote supervision. This could dramatically improve accessibility, particularly for patients in rural or remote areas.

Combination therapy approaches are gaining research attention as well. These involve strategically pairing TMS with other interventions—perhaps specific cognitive tasks, virtual reality environments, or particular medication regimens—to potentially enhance outcomes beyond what either approach could achieve alone.

We're also seeing advances in neuronavigation and targeting. Rather than using standardized anatomical landmarks to position the coil, newer approaches use individual brain scans and computational models to identify the optimal stimulation target for each patient based on their unique brain structure and connectivity patterns.

Finally, adaptive protocols that adjust based on ongoing response are being developed. These would use real-time data about brain activity and symptom changes to modify stimulation parameters throughout the treatment course, creating a more dynamically personalized approach.

Interviewer: What should patients understand about the balance between established evidence and emerging possibilities in TMS treatment?

Research Psychologist: This is a crucial distinction. When considering TMS therapy, patients should understand that applications exist along a spectrum of evidence.

Depression treatment has the strongest evidence base, with numerous large controlled trials, FDA approval, and Medicare recognition. This represents the most established application with the most predictable outcomes and clearest protocols.

Anxiety disorders, OCD, and PTSD have growing evidence bases with some positive controlled trials, but fewer than depression. These applications are supported by reasonable evidence but are still evolving in terms of optimal protocols and patient selection.

Applications like pain management, cognitive enhancement, or substance use disorders remain more experimental, with promising preliminary research but less established clinical protocols and more variable outcomes.

For patients considering TMS, I recommend focusing primarily on its established applications while maintaining appropriate expectations for emerging ones. If seeking TMS for depression, you can approach it as a mainstream, evidence-based treatment. If considering it for other conditions, it's reasonable to view it as a promising alternative when conventional approaches haven't worked, while recognizing the evidence base is still developing.

It's also worth understanding that TMS research continues to evolve rapidly. An application considered experimental today might have substantial supporting evidence in a few years. This dynamic nature is exciting but requires carefully evaluating the current state of evidence for your specific condition when making treatment decisions.

​

​

Find us:

https://medium.com/@services297/neuralia-tms-53145185064b

https://foursquare.com/v/neuralia-tms/6809dcf3b44c043a6981a628

https://www.yelp.com.au/user_details?userid=sKQtgyXB9gSt5F6zNiCP4Q